Company intelligence / Profile preview

Shanghai Fangxin Technology

Shanghai, Shanghai, China6sense.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has been involved in research and development of more than 20 projects including innovative medicines, generic drugs and medical equipment. As of 2021, 2 projects had been submitted for clinical practice, 1 project received clinical approvals, and 6 projects were to be declared[3].

Therapeutic areas: Pulmonology
Industry: Biotech

Drug pipeline

1 asset

Shegan Mixture

Commercial

Indications: Asthma

Partnerships

Partnered with the Guangzhou Institute of Respiratory Diseases led by Academician Zhong Nanshan[3]

Beyond the preview

Go deeper on Shanghai Fangxin Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Fangxin Technology.

Explore the full profile